Express News | Zenas Biopharma Inc Says Bristol-Myers Squibb Co, Xencor Inc Are Among 5% or Greater Stockholders in the Company
Leerink Partners Maintains Xencor(XNCR.US) With Buy Rating, Raises Target Price to $32
Buy Rating Affirmed for Xencor on Promising XmAb819 Developments and Strong Strategic Position
Express News | Xencor Inc : Leerink Partners Raises Target Price to $32 From $29
Xencor (NASDAQ:XNCR) Shareholders Are up 6.7% This Past Week, but Still in the Red Over the Last Five Years
Express News | Xencor Inc : BofA Global Research Cuts Price Objective to $32 From $34
Buy Rating Affirmed for Xencor Amid Strong Drug Pipeline and Financial Health
Express News | Xencor Inc : Leerink Partners Cuts Target Price to $29 From $35
Wedbush Maintains Xencor(XNCR.US) With Buy Rating, Cuts Target Price to $34
Express News | RBC Capital Reiterates Outperform on Xencor, Maintains $31 Price Target
A Quick Look at Today's Ratings for Xencor(XNCR.US), With a Forecast Between $21 to $34
Buy Rating Affirmed for Xencor Owing to Strong Pipeline Progress and Financial Stability
RBC Capital Sticks to Their Buy Rating for Xencor (XNCR)
Xencor (XNCR) Receives a Buy From TD Cowen
Express News | Xencor : Expects to End 2024 With Between $475 Mln and $525 Mln in Cash, to Have Cash to Fund R&D Programs & Opers Into 2027
Xencor | 10-Q: Q2 2024 Earnings Report
Xencor Q2 EPS $(1.07) Misses $(0.88) Estimate, Sales $16.96M Beat $15.83M Estimate
Earnings Flash (XNCR) XENCOR Posts Q2 Loss $-1.07
Xencor: Based on Current Operating Plans, Xencor Expects to End 2024 With Between $475M and $525M in Cash, Cash Equivalents and Marketable Debt Securities
Express News | Xencor Reports Second Quarter 2024 Financial Results